| Name | Title | Contact Details |
|---|
The Minnesota Twins are a professional baseball team based in Minneapolis, Minnesota. They play in the Central Division of Major League Baseballs American League. Winners of the 1987 and 1991 World Series. Stay up to date on everything about the Twins at www.twinsbaseball.com
Founded in 1996, Swarts, Manning & Associates has quickly established itself as a leader in the insurance industry. As a full-service agency, Swarts, Manning & Associates is dedicated to providing the most comprehensive, customized, and cost-effective insurance solutions available. With specialized departments dedicated to customizing protection for your business, you will partner with an industry expert to assist with your unique risk management needs. Our dedication to customer service and our knowledgeable, friendly staff are just a few of the reasons why Swarts, Manning & Associates stands as a leader and innovator within the insurance industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.